148 related articles for article (PubMed ID: 16357945)
21. [Construction of pharmacophore model of PARP-1 inhibitor].
Zhang WT; Yan H; Jiang FC
Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827
[TBL] [Abstract][Full Text] [Related]
22. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
23. [Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
Boulu RG; Mesenge C; Charriaut-Marlangue C; Verrecchia C; Plotkine M
Bull Acad Natl Med; 2001; 185(3):555-63; discussion 564-5. PubMed ID: 11501263
[TBL] [Abstract][Full Text] [Related]
24. PISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situ.
Lubbers LS; Rowe BA; Hodge LM; Browne SE; Gundersdorf R; Jones P; Hess FJ; Reynolds IJ
J Pharmacol Toxicol Methods; 2010; 61(3):319-28. PubMed ID: 20132901
[TBL] [Abstract][Full Text] [Related]
25. Poly(ADP-ribose)polymerase inhibition - where now?
Woon EC; Threadgill MD
Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
[TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Pieper AA; Verma A; Zhang J; Snyder SH
Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
[TBL] [Abstract][Full Text] [Related]
27. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
[TBL] [Abstract][Full Text] [Related]
28. Mediation of cell death by poly(ADP-ribose) polymerase-1.
Koh DW; Dawson TM; Dawson VL
Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329
[TBL] [Abstract][Full Text] [Related]
29. Nonisotopic methods for determination of poly(ADP-ribose) levels and detection of poly(ADP-ribose) polymerase.
Haince JF; Poirier GG; Kirkland JB
Curr Protoc Cell Biol; 2004 Feb; Chapter 18():Unit18.7. PubMed ID: 18228447
[TBL] [Abstract][Full Text] [Related]
30. 3. Life or death decisions: the cast of poly(ADP-ribose)polymerase (PARP) as a therapeutic target for brain ischaemia.
Pellicciari R; Camaioni E; Costantino G
Prog Med Chem; 2004; 42():125-69. PubMed ID: 15003720
[No Abstract] [Full Text] [Related]
31. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
[TBL] [Abstract][Full Text] [Related]
32. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
33. [Poly(ADP-ribosa)polymerase--the relationships with life span and carcinogenesis].
Piskunova TS; Iurova MN; Zabezhinskiĭ MA; Anisimov VN
Adv Gerontol; 2007; 20(2):82-90. PubMed ID: 18306694
[TBL] [Abstract][Full Text] [Related]
34. Disparity in the induction of glutathione depletion, ROS formation, poly(ADP-ribose) polymerase-1 activation, and apoptosis by quinonoid derivatives of naphthalene in human cultured cells.
Lin CH; Huang CC; Wang TW; Wang YJ; Lin PH
Chem Biol Interact; 2007 Feb; 165(3):200-10. PubMed ID: 17224139
[TBL] [Abstract][Full Text] [Related]
35. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
36. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
Mathews MT; Berk BC
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):711-7. PubMed ID: 18239155
[TBL] [Abstract][Full Text] [Related]
37. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Kauppinen TM; Swanson RA
Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
[TBL] [Abstract][Full Text] [Related]
38. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.
Cockcroft XL; Dillon KJ; Dixon L; Drzewiecki J; Kerrigan F; Loh VM; Martin NM; Menear KA; Smith GC
Bioorg Med Chem Lett; 2006 Feb; 16(4):1040-4. PubMed ID: 16290932
[TBL] [Abstract][Full Text] [Related]
39. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
Moroni F
Curr Opin Pharmacol; 2008 Feb; 8(1):96-103. PubMed ID: 18032109
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Iwashita A; Yamazaki S; Mihara K; Hattori K; Yamamoto H; Ishida J; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Jun; 309(3):1067-78. PubMed ID: 14985416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
